Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor - film coated tablets - ivacaftor 150 mg - ivacaftor - kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (cf) aged 6 years and older and weighing 25 kg or more who have one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r.limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor - film coated tablets - ivacaftor 150 mg - ivacaftor - kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (cf) aged 6 years and older and weighing 25 kg or more who have one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r.limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor - film coated tablets - ivacaftor 150 mg - ivacaftor - kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (cf) aged 6 years and older and weighing 25 kg or more who have one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r.limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor - granules - ivacaftor 50 mg - ivacaftor - kalydeco granules are indicated for the treatment of children with cystic fibrosis (cf) aged 2 years and older and weighing less than 25 kg who have one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r. limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene.

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor - granules - ivacaftor 75 mg - ivacaftor - kalydeco granules are indicated for the treatment of children with cystic fibrosis (cf) aged 2 years and older and weighing less than 25 kg who have one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r. limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene.

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; tezacaftor - film coated tablets - ivacaftor 150 mg; tezacaftor 100 mg - ivacaftor and tezacaftor - symdeko is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (cf) aged 12 years and older who are homozygous for the f508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.if the patient’s genotype is unknown, a health authority cleared cf mutation test should be used to detect the presence of a cftr mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; tezacaftor - film coated tablets - ivacaftor 150 mg; tezacaftor 100 mg - ivacaftor and tezacaftor - symdeko is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (cf) aged 12 years and older who are homozygous for the f508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.if the patient’s genotype is unknown, a health authority cleared cf mutation test should be used to detect the presence of a cftr mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor - granules - ivacaftor 50 mg - ivacaftor - kalydeco granules are indicated for the treatment of children with cystic fibrosis (cf) aged 2 years and older and weighing less than 25 kg who have one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data. limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene.